Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

HKG:1349 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,274	1,147	1,056	1,196	1,289	1,209
Short-Term Investments	-	-	-	-	30	-
Cash & Short-Term Investments	1,274	1,147	1,056	1,196	1,319	1,209
Cash Growth	13.89%	8.60%	-11.67%	-9.35%	9.13%	-13.46%
Accounts Receivable	260.27	297.75	469.96	620.49	679.12	672.49
Other Receivables	1.12	0.31	1.08	0.16	5.14	1.18
Receivables	261.39	298.07	471.04	620.64	684.26	673.66
Inventory	27.12	33.21	47.27	43.65	40.53	35.63
Other Current Assets	11.71	7.16	32.18	9.24	25.1	9.77
Total Current Assets	1,574	1,486	1,607	1,869	2,069	1,928
Property, Plant & Equipment	441.12	477.25	503.53	475.33	351.51	301.92
Long-Term Investments	223.72	229.07	257.49	287.53	306.37	327.86
Other Intangible Assets	52.12	60.87	68.65	86.35	62.32	88.46
Long-Term Deferred Tax Assets	131.41	131.41	133.28	100.87	85.9	79.22
Long-Term Deferred Charges	5.12	4.41	9.28	-	43.09	36.12
Other Long-Term Assets	5.05	2.12	7.5	57.18	57.62	19.64
Total Assets	2,433	2,391	2,587	2,877	2,976	2,781

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	7.56	6.07	10.67	8.05	7.43	8.17
Accrued Expenses	17.13	171.35	167.57	36.86	34.67	53.78
Short-Term Debt	-	-	-	-	101	-
Current Portion of Leases	-	5.35	6.1	6.33	8.22	8.68
Current Income Taxes Payable	11.46	-	-	1.61	1.63	10.4
Current Unearned Revenue	3.61	5.41	8.34	0.26	0.31	348.87
Other Current Liabilities	210.6	57.45	58.27	451.9	520.09	98.3
Total Current Liabilities	255.8	245.62	250.95	505.02	673.34	528.2
Long-Term Leases	5.2	9.34	14.43	10.95	15.6	22.59
Long-Term Unearned Revenue	17.35	18.97	15.85	2.15	34.04	40.8
Total Liabilities	278.35	273.93	281.23	518.12	722.99	591.58

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	103.66	103.66	103.66	103.66	102.9	104.3
Additional Paid-In Capital	1,291	1,290	1,290	1,289	1,225	1,265
Retained Earnings	766.78	728.37	916.9	970.46	934.39	868.43
Treasury Stock	-	-	-	-	-	-40.82
Comprehensive Income & Other	-6.85	-6.05	-5.55	-5.86	-5.2	-4.05
Total Common Equity	2,154	2,116	2,305	2,358	2,257	2,193
Minority Interest	0.22	0.43	0.71	1.01	-4.08	-3.36
Shareholders' Equity	2,154	2,117	2,305	2,359	2,253	2,190
Total Liabilities & Equity	2,433	2,391	2,587	2,877	2,976	2,781

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	10.65	14.69	20.53	17.28	124.81	31.26
Net Cash (Debt)	1,263	1,132	1,036	1,179	1,194	1,178
Net Cash Growth	14.57%	9.33%	-12.12%	-1.33%	1.43%	-14.49%
Net Cash Per Share	1.09	1.09	1.00	1.14	1.16	1.13
Filing Date Shares Outstanding	807.6	1,037	1,037	1,037	1,029	1,032
Total Common Shares Outstanding	807.6	1,037	1,037	1,037	1,029	1,032
Working Capital	1,318	1,240	1,356	1,364	1,396	1,400
Book Value Per Share	2.67	2.04	2.22	2.27	2.19	2.12
Tangible Book Value	2,102	2,055	2,236	2,271	2,195	2,104
Tangible Book Value Per Share	2.60	1.98	2.16	2.19	2.13	2.04
Buildings	-	396.73	368.53	199.22	198.52	198.52
Machinery	-	500.03	504.91	388.63	341.74	322.86
Construction In Progress	-	0.19	7.2	229.96	122.37	48.9

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error